RESEARCH TRIANGLE PARK, N.C. - June 9, 1998 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the opening of offices in Bulgaria and Hungary, further expanding its ability to provide pharmaceutical development services in Eastern Europe.
Located in the capital cities of Sofia, Bulgaria, and Budapest, Hungary, the offices will complement Quintiles' other clinical monitoring and regulatory affairs capabilities in Central and Eastern Europe.
"Our customers are increasingly conducting studies on a global basis, including in Central and Eastern Europe," said Heinz Carmann, M.D., managing director of Quintiles GesmbH Vienna, Austria, who oversees Quintiles' operations in Central and Eastern Europe. "We believe that Eastern Europe's large population - more than 400 million people - and the strong governmental support we've received in Bulgaria and Hungary make these favorable locations for Quintiles."
In addition to Bulgaria and Hungary, Quintiles currently is managing clinical trials in Austria, Russia, Poland, the Czech Republic, Slovakia, Belarus, Romania, Serbia, Croatia and Slovenia.
The Bulgaria office, with six employees, is headed by Jordanka Mircheva, M.D. The address is Saborna Street 4, vh B et 1 ap 3, 1000 Sofia, Bulgaria. Telephone: +35 92 817306. The Hungary office, with 19 employees, is managed by Sarolta Ronai, Ph.D. The address is Nemetvolgyi ut 98.H-1124 Budapest, Hungary. Telephone: +36 1 319 1616.
Quintiles Transnational Corp. is the market leader in providing full-service contract research, sales and marketing, healthcare policy consulting and health information management services to the worldwide pharmaceutical, biotechnology, medical device and healthcare industries. Quintiles is headquartered near Research Triangle Park, North Carolina. With 13,000 employees worldwide and offices in 28 countries, Quintiles operates through specialized work groups dedicated to meeting individual customer needs.